Teruo Yamauchi

Faculty & Position:Medical Oncology Department  doctor
Last Updated: Sep. 01, 2020 at 05:06

Researcher Profile & Settings


  • Sep. 2007Jul. 2009University of South Florida College of Medicine
  • Apr. 1982Mar. 1988Kagoshima University Faculty of Medicine

Academic & Professional Experience

  • Jul. 2009- TodayChief, Division of Medical Oncology, St. Luke's International Hospital
  • Jul. 2004Jun. 2005Chief Resident, Clinical Instructor, Internal Medicine, University of Hawaii

Research Activities

Research Areas

  • Life sciences / Tumor diagnostics and therapeutics

Published Papers

  • Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy.
    Komatsu H, Yagasaki K, Komatsu Y, Yamauchi H, Yamauchi T, Shimokawa T, Doorenbos AZ
    Asia-Pacific journal of oncology nursing 6(3) 253-260 Jul. 2019 [Refereed]
  • Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients
    Okumatsu K, Tsujimoto T, Wakaba K, Seki A, Kotake R, Yamauchi T, Hirayama H, Kobayashi H, Yamauchi H, Tanaka K
    Breast Cancer 26 72-73 Sep. 2018 [Refereed]
  • Factors associated to treatment delay in women with primary breast cancer who were referred to reproductive specialists
    Kitano Atsuko, Ohde Sachiko, Shiota Kyoko, Akitani Fumi, Yamauchi Hideko, Yamauchi Teruo
    JOURNAL OF CLINICAL ONCOLOGY 36(15) May 2018 [Refereed]
  • Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.
    Teruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, Hideko Yamauchi, Hiromitsu Jinno, Maiko Takahashi, Yuko Kitagawa, Seigo Nakamura, Bora Lim, Savitri Krishnamurthy, James M Reuben, Diane Liu, Debasish Tripathy, Helen Chen, Naoko Takebe, Hideyuki Saya, Naoto T Ueno
    Oncotarget 9(6) 6872-6882 Jan. 2018 [Refereed]
    Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy. In a prospective clinical trial to evaluate pharmacodynamic biomarkers, 18 patients with operable primary HER2-positive breast cancer received dual anti-Her2 preoperative therapy with trastuzumab and lapatinib with paclitaxel. Proportions of tumor cells with CSC characteristics and EMT markers in CTC's were estimated at baseline, after 6 and 18 weeks of preoperative therapy to determine the quantitative cutoff value to predict pathologic complete response (pCR). Out of 18 patients, 8 (44%) had a pCR; 5 of these 8 patients (62%) were positive for CD44v at baseline and none were positive on the 6-week biopsy. In contrast, 6 of the 10 patients without pCR exhibited persistent levels, or enrichment of CD44v proportion and expression at 6 and 18 weeks (p=0.0128). Other biomarkers were not statistically significant predictors of pCR. Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy.
  • Physical fitness level in Japanese breast cancer survivors
    Okumatsu,Koki, Tsujimoto,Takehiko, Wakaba,Kyosuke, Seki,Akina, Kotake,Rina, Yamauchi,Teruo, Hirayama,Satoshi, Kobayashi,Hiroyuki, Bando,Hiroko, Yamauchi,Hideko, Tanaka,Kiyoji
    Japanese Journal of Physical Fitness and Sports Medicine 67(2) 169-176 2018 [Refereed]
    <p>It has been reported that physical fitness of breast cancer patients is relatively lower due to the cancer treatment such as surgery, chemotherapy, or endocrine therapy. Previous studies have revealed that not only cardiorespiratory fitness but also muscle strength is lower among breast cancer patients than no disease women and these symptoms may aggravate the health-related quality of life. However, there is no study which has focused the physical fitness level in Japanese breast cancer survivors. The purpose of this study was to investigate the physical fitness level and the relationship between exercise habituation and physical fitness level in Japanese breast cancer survivors. Fifty breast cancer survivors participated in this study. Participants were assigned to either exercise habituation group (n=25) or non-exercise group (n=25). We evaluated exercise habituation using an original questionnaire and examined various physical fitness level. Body weight, body mass index, and percent body fat were significantly lower in the exercise habituation group than non-exercise group. T-score of cardiorespiratory fitness was significantly higher in the exercise habituation group than a
  • Mucin-poor and aggressive mucinous tubular and spindle cell carcinoma of the kidney: Two case reports.
    Uchida S, Suzuki K, Uno M, Nozaki F, Li CP, Abe E, Yamauchi T, Horiuchi S, Kamo M, Hattori K, Nagashima Y
    Molecular and clinical oncology 7(5) 777-782 Nov. 2017 [Refereed]
  • A self-directed home yoga programme for women with breast cancer during chemotherapy: A feasibility study.
    Hiroko Komatsu, Kaori Yagasaki, Hideko Yamauchi, Teruo Yamauchi, Toru Takebayashi
    International journal of nursing practice 22(3) 258-66 Jun. 2016 [Refereed]
    Recent studies suggest yoga as a promising approach for improving the cognitive function of cancer survivors. We studied whether a self-directed home yoga programme was feasible for patients with breast cancer who were undergoing chemotherapy. Participants' preferences for the type of yoga course and the clinical effects of the programme were also assessed. In this study, 18 women (mean age, 43.9 years) were enrolled (44.7% recruitment rate). Of the participants, 63.6% had stage II cancer and 71.4% received adjuvant chemotherapy. Favourable retention (86%), adherence (94.4%) and acceptability (96.5%) rates were determined. Most (94.4%) of the women practiced the home programme more than twice a week on average. The participants preferred to gradually increase the intensity of the exercises. We only observed improvements in the cognitive aspects of fatigue. No serious adverse events were encountered during the programme. This self-directed home yoga programme was safe and feasible for patients with breast cancer undergoing chemotherapy.
  • Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy.
    Masahiko Sumitani, Toru Ogata, Akina Natori, Jun Hozumi, Nobutake Shimojo, Kumiko Kida, Hideko Yamauchi, Teruo Yamauchi
    Biomedical reports 4(6) 758-760 Jun. 2016 [Refereed]
    The phosphorylated form of the high-molecular-weight neurofilament heavy subunit (pNF-H) is a major structural protein in axons. The pNF-H level is elevated in the serum of certain patients with central nervous disorders, including chemotherapy-induced cognitive impairment. The present study was conducted to elucidate the potential role of pNF-H as a marker of chemotherapy-induced peripheral neuropathy (CIPN). A total of 71 patients with early breast cancer in various stages of treatment (following 1, 3 or 7 cycles of chemotherapy, or a previous history of breast cancer chemotherapy) were assessed with a self-administered PainDETECT questionnaire [pain location, pain intensity on an 11-point numeric rating scale (NRS), and various pain qualities] and a single serum pNF-H measurement. Patients were divided into two groups based on the presence or absence of bilateral symmetric pain in the distal portions of the extremities [CIPN(+) or CIPN(-)]. The χ2 and Mann-Whitney tests were used for statistical analyses. Among the participants, only 8 patients complained of CIPN. Their pain intensity was 3.5±1.9 (mean ± standard deviation) compared with 1.5±1.8 in the CIPN(-) group (P<0.01). The NRS of numbness in the CIPN(+) group was significantly higher (2.4±1.4) than that of the CIPN(-) group (1.0±1.0). Increased pNF-H levels were observed in 37.5% of the CIPN(+) patients and in 23.8% of CIPN(-) patients (P=0.40). In conclusion, CIPN is observed in the most distal portions of the peripheral nerves that are composed of dendrites but not axons. Although serum pNF-H is a biomarker of axonal damage, it is not useful as a marker of CIPN.
  • Patients' Perspectives on Creating a Personal Safety Net During Chemotherapy.
    Hiroko Komatsu, Kaori Yagasaki, Hideko Yamauchi, Teruo Yamauchi
    Clinical journal of oncology nursing 20(1) 13-6 Feb. 2016 [Refereed]
    Nurses are critical to the physical management and psychological support of patients undergoing chemotherapy, which is a vulnerable time for many. This article presents the results of a qualitative study intended to explore the experience of Japanese patients with breast cancer during chemotherapy, including the finding that participants created personal safety nets in physical, emotional, and social contexts that helped them to gain confidence in their ability to exert control over their lives. Understanding each patient's personal safety net allows nurses to support their patients in maintaining and improving their function and well-being.
  • Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
    Richard Kim, Teruo Yamauchi, Kazim Husain, Said Sebti, Mokenge Malafa
    Anticancer research 35(9) 4599-604 Sep. 2015 [Refereed]
    BACKGROUND: Pancreatic cancer is a highly lethal cancer due to early metastasis and resistance to current chemotherapeutic agents. Abnormal protein kinase B (AKT) activation is an important mechanism of chemoresistance to gemcitabine, the most widely used agent in pancreatic cancer. MATERIAL AND METHODS: In the study, we tested the hypothesis that combining an AKT inhibitor with gemcitabine would augment anti-tumor activity. We treated human pancreatic cancer MiaPaCa-2 cells with gemcitabine and the AKT inhibitor triciribine, alone and in combination, and evaluated treatment effects using trypan blue assay, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium (MTT) assay, and cell death enzyme-linked immunosorbant assay. Colorimetric data of MTT assay were computationally analyzed for synergism of the combination therapy by CalcuSyn2 (Biosoft, Great Shelford, Cambridge, UK). RESULTS: Both gemcitabine and triciribine inhibited cell growth in a dose-dependent manner. Triciribine synergistically enhanced the cytotoxic activity of gemcitabine. The combination index (CI) provides the synergistic, additive, or antagonistic effects of the two-drug combination. CI at the 50% effective dose at 1:500 ratio of gemcitabine to triciribine was 0.74, indicating the synergistic effect of the drugs. The combination treatment with the non-apoptotic dose of each agent distinctly induced apoptosis, with gemcitabine in combination with triciribine, synergistically inhibiting pancreatic cancer cell growth and inducing apoptosis. CONCLUSION: These findings support the use of triciribine to overcome activated AKT-mediated resistance of pancreatic cancer to gemcitabine.
  • Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment.
    Akina Natori, Toru Ogata, Masahiko Sumitani, Takamichi Kogure, Teruo Yamauchi, Hideko Yamauchi
    Clinical cancer research : an official journal of the American Association for Cancer Research 21(6) 1348-52 Mar. 2015 [Refereed]
    PURPOSE: Chemotherapy-induced cognitive impairment (CICI) is a clinically significant problem. Previous studies using magnetic resonance imaging indicated structural changes in the cerebral white matter of patients with CICI. Phosphorylated neurofilament heavy subunit (pNF-H), a major structural protein in axons, was recently reported to be elevated in the serum of patients with some central nervous system disorders. We performed a cross-sectional analysis of neuropsychological test results and serum pNF-H levels in patients undergoing adjuvant chemotherapy for breast cancer. Our hypothesis was that CICI is accompanied by axonal damage that can be detected by elevated serum pNF-H levels. EXPERIMENTAL DESIGN: Seventy-six patients with early breast cancer in various phases of treatment (naïve to chemotherapy; after one, three, or seven cycles of chemotherapy; or with a history of chemotherapy) were assessed by self-administered neuropsychological tests and a single pNF-H measurement. The χ(2) and Mann-Whitney tests were used for statistical analysis. RESULTS: Increased pNF-H levels were observed in 28.8% of the patients who underwent chemotherapy, but in none of the chemotherapy-naïve patients or patients with a history of chemotherapy. The pNF-H-positive rate increased significantly in proportion to the number of chemotherapy cycles (one cycle, 5.0%; three cycles, 31.6%; seven cycles, 55.0%; P < 0.05). No significant differences in neuropsychological test results were observed among the groups. CONCLUSIONS: The serum pNF-H level in patients undergoing chemotherapy for breast cancer increased in a cumulative dose-dependent manner, suggesting its potential application as a biomarker of neural damage after chemotherapy.
  • Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Takeo Fujii, Naoki Nishimura, Kevin Y Urayama, Hisako Kanai, Hiromasa Ishimaru, Junko Kawano, Osamu Takahashi, Hideko Yamauchi, Teruo Yamauchi
    Anticancer research 35(1) 379-83 Jan. 2015 [Refereed]
    BACKGROUND: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. RESULTS: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.
  • Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
    Kazim Husain, Rony A Francois, Teruo Yamauchi, Marta Perez, Said M Sebti, Mokenge P Malafa
    Molecular cancer therapeutics 10(12) 2363-72 Dec. 2011 [Refereed]
    The NF-κB transcription factor functions as a crucial regulator of cell survival and chemoresistance in pancreatic cancer. Recent studies suggest that tocotrienols, which are the unsaturated forms of vitamin E, are a promising class of anticancer compounds that inhibit the growth and survival of many cancer cells, including pancreatic cancer. Here, we show that tocotrienols inhibited NF-κB activity and the survival of human pancreatic cancer cells in vitro and in vivo. Importantly, we found the bioactivity of the four natural tocotrienol compounds (α-, β-, δ-, and γ-tocotrienol) to be directly related to their ability to suppress NF-κB activity in vitro and in vivo. The most bioactive tocotrienol for pancreatic cancer, δ-tocotrienol, significantly enhanced the efficacy of gemcitabine to inhibit pancreatic cancer growth and survival in vitro and in vivo. Moreover, we found that δ-tocotrienol augmentation of gemcitabine activity in pancreatic cancer cells and tumors is associated with significant suppression of NF-κB activity and the expression of NF-κB transcriptional targets (Bcl-X(L), X-linked inhibitor of apoptosis, and survivin). Our study represents the first comprehensive preclinical evaluation of the activity of natural vitamin E compounds in pancreatic cancer. Given these results, we are conducting a phase I trial of δ-tocotrienol in patients with pancreatic cancer using pancreatic tumor cell survival and NF-κB signaling components as intermediate biomarkers. Our data also support future clinical investigation of δ-tocotrienol to augment gemcitabine activity in pancreatic cancer.
  • Metabolic abnormalities associated with atypical antipsychotics: a case report and alert.
    Yamauchi T, Tice A
    Hawaii medical journal 66(1) 12-13 Jan. 2007 [Refereed]

Conference Activities & Talks

  • 乳癌患者の抗がん剤投与に伴う頭皮生理機能と症状の変化
    玉井 奈緒, 池田 真理, 江口 華子, 細川 恵子, 金井 久子, 山内 英子, 山内 照夫, 真田 弘美
    日本乳癌学会総会プログラム抄録集 Jun. 2016
  • がん化学療法を受ける患者の見た目の変化の実態と外見を整えるためのケアに関するアンケート
    大畑 美里, 金井 久子, 猪原 彩子, 立花 夏子, 中野 和季, 大出 幸子, 山内 照夫
    日本がん看護学会誌 Jan. 2015
  • 当院におけるエリブリンの治療成績および減量時期,副作用の変化についての検討
    北野敦子, 山内照夫
    日本臨床腫瘍学会学術集会(CD-ROM) 2014
  • がん疼痛マネジメントに対する患者の心理的バリア評価指標の開発 日本語版The Barriers Questionnaire IIの検証
    榊原 直喜, 小松 浩子, 高橋 美賀子, 山内 英子, 山内 照夫
    日本がん看護学会誌 Jan. 2014
  • 経口低用量シクロホスファミド(CPA)の長期服用による出血性膀胱炎
    永野 悦子, 田原 麻理, 山内 照夫
    日本乳癌学会総会プログラム抄録集 May 2012
  • 米国NCIとのコラボレーションによる医師主導治験
    山内 照夫, 今村 知世, 甲斐 千晴, 神野 浩光, 山内 英子, 北川 雄光, 佐谷 秀行, 中村 清吾, 上野 直人
    日本乳癌学会総会プログラム抄録集 May 2012
  • 経口抗がん剤シクロホスファミド(CPA)治療による治療関連性白血病を発症した乳がん患者の一例
    永野 悦子, 山内 照夫
    日本がん看護学会誌 Jan. 2012
  • 医薬品のグローバル開発における日本の貢献・日本の役割 米国NCIとのコラボレーションによる医師主導治験
    今村 知世, 山内 照夫, 山内 英子, 中村 清吾, 神野 浩光, 北川 雄光, 佐谷 秀行, 上野 直人
    臨床薬理 Oct. 2011
  • 血管ベーチェット病に腸管ベーチェット病を併発した一例
    山内 照夫
    日本内科学会関東地方会抄録集 Mar. 1991
  • 膵頭部癌との鑑別が困難であった総胆管・膵管断端神経腫の1例
    山内 照夫
    日本消化器病学会雑誌 Mar. 1990


  • 遺伝性腫瘍の診療体制の構築に向けて がん遺伝子パネル検査で得られた情報を日常臨床に応用する上での課題
    大川 恵, 鈴木 美慧, 金井 久子, 竹井 淳子, 吉田 敦, 山内 照夫, 山中 美智子, 山内 英子
    日本乳癌学会総会プログラム抄録集 26回 300-300 May 2018
  • BRCA変異陽性転移性乳癌に対するオラパリブ単独療法と化学療法を比較する第III相試験(OlympiAD)
    岩田 広治, 増田 慎三, 山内 照夫, 中村 清吾, 徳永 えり子, 高橋 將人, 田村 研治, 雷 哲明, 金 昇晋, 六反田 奈和
    日本乳癌学会総会プログラム抄録集 26回 336-336 May 2018
  • BRCA変異陽性転移性乳癌に対するオラパリブ単独療法と化学療法を比較する第III相試験(OlympiAD)HRQoLの評価
    山内 照夫, 増田 慎三, 岩田 広治, 中村 清吾, 徳永 えり子, 高橋 將人, 田村 研治, 雷 哲明, 金 昇晋, 六反田 奈和
    日本乳癌学会総会プログラム抄録集 26回 339-339 May 2018
  • キャッチ!オンコロ・トレンド(第2回) 「遺伝看護専門看護師」の誕生と「がん領域の遺伝看護」のこれから
    大川 恵, 山内 照夫, 武田 祐子
    YORi-SOUがんナーシング 8(2) 170-171 Apr. 2018
  • 【がん:検診、ケア、予防、運動習慣化の意義を考える】 日本人乳がんサバイバーの体力水準
    奥松 功基, 辻本 健彦, 若葉 京良, 関 晶南, 固武 利奈, 山内 照夫, 平山 智志, 小林 裕幸, 坂東 裕子, 山内 英子, 田中 喜代次
    体力科学 67(2) 169-176 Apr. 2018
  • Evidence "The Classic" Review《乳がん》 Before and After Trastuzumab 乳がん分子標的治療薬の先駆者トラスツズマブ
    山内 照夫
    Cancer Board Square 3(2) 316-317 Jul. 2017
  • 【がん診療-内科医が知りたい30のエッセンス】 本音で語る がん診療における内科医の役割
    山内 照夫, 佐野 潔, 東 光久
    Medicina 54(8) 1174-1181 Jul. 2017
  • 【がん診療-内科医が知りたい30のエッセンス】内科医が知っておくべきがん診療の基本 がん診療に必要な基本知識 どのように診断し,治療が行われていくのでしょうか
    山内 照夫
    Medicina 54(8) 1192-1195 Jul. 2017
  • 抗悪性腫瘍薬の有害事象に対するマネジメント 発熱性好中球減少への対処から骨塩量低下に対する支持療法まで トラスツズマブ使用原発乳癌患者における心筋障害の評価検討についての前向きコホート研究
    中山 可南子, 松田 直子, 藤井 健夫, 水野 篤, 大出 幸子, 山内 照夫, 山内 英子
    日本乳癌学会総会プログラム抄録集 25回 222-222 Jul. 2017
  • がん患者における運動と栄養の重要性
    田中 喜代次, 山内 英子, 関 晶南, 山内 照夫, 奥松 功基, 平山 智志, 中川 ひろみ, 西澤 祐吏, 伊藤 雅昭
    Palliative Care Research 12(Suppl.) S310-S310 Jun. 2017
  • 平成28年度日本体育協会スポーツ医・科学研究報告II 運動・スポーツ習慣の定着を企図した健幸華齢支援プログラムの開発(第1報)(第3章) 様々な対象者への運動プログラム提供例(報告) 乳がん患者の内省報告・感想「健康づくり教室に参加して」
    田中 喜代次, 奥松 功基, 辻本 健彦, 若葉 京良, 王 震男, 谷口 亮介, 梅村 貴, 平山 智志, 関 晶南, 固武 利奈, 山内 照夫, 山内 英子
    日本体育協会スポーツ医・科学研究報告集 2016年度 23-25 Mar. 2017
  • 【これだけは押さえておきたい がん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬・支持療法薬 はや調べノート2017・2018年版】 従来型 葉酸拮抗薬 メトトレキサート
    山内 照夫
    プロフェッショナルがんナーシング(2017別冊) 120-121 Feb. 2017
  • 【これだけは押さえておきたい がん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬・支持療法薬 はや調べノート2017・2018年版】 従来型 葉酸拮抗薬 ペメトレキセドナトリウム水和物
    山内 照夫
    プロフェッショナルがんナーシング(2017別冊) 122-123 Feb. 2017
  • 【いつ・誰に尋ねられてももう困らない!がん化学療法 薬の知識アップデート すぐに役立つ最新Q&A】 ズバリ!薬物療法Q&A まずはおさえておきたい注目ワード 免疫チェックポイント阻害薬 最近話題の免疫チェックポイント阻害薬は、免疫療法の1つとのことですが、自由診療で行われている免疫療法とは異なるのですか?両方の治療を受けても大丈夫でしょうか
    矢崎 秀, 山内 照夫
    ナーシング 37(2) 11-12 Jan. 2017
  • 乳癌患者の抗がん剤投与に伴う頭皮生理機能と症状の変化
    玉井 奈緒, 池田 真理, 江口 華子, 細川 恵子, 金井 久子, 山内 英子, 山内 照夫, 真田 弘美
    日本乳癌学会総会プログラム抄録集 24回 254-254 Jun. 2016
  • 【がんサバイバーシップ】 分子標的薬の副作用対策
    山内 照夫
    治療 97(10) 1393-1398 Oct. 2015
  • 【緩和医療の今】 症状緩和の今 痛み がん性疼痛の基礎
    住谷 昌彦, 穂積 淳, 山内 照夫
    ペインクリニック 36(別冊秋) S361-S370 Oct. 2015
  • 【緩和ケアチームが切り拓くがん疼痛治療の新たな地平】 緩和ケアチームだからできる治療抵抗性疼痛の治療 がん関連神経障害性疼痛への集学的な対応
    住谷 昌彦, 四津 有人, 山内 照夫
    がん患者と対症療法 26(1) 55-60 Aug. 2015
  • 神経軸索損傷バイオマーカーpNF-Hは化学療法誘発性ニューロパチーの客観的指標にはならない
    住谷 昌彦, 緒方 徹, 名取 亜希奈, 穂積 淳, 稲田 修士, 金井 良晃, 海津 未希子, 三浦 恵美子, 坂田 尚子, 山内 英子, 山内 照夫
    日本緩和医療学会学術大会プログラム・抄録集 20回 188-188 Jun. 2015
  • 【痛み治療の素朴な疑問に答えます1】 トラマドールの使い分け 三つの剤型の特徴
    住谷 昌彦, 山内 照夫
    LiSA 22(1) 14-16 Jan. 2015
  • 【ペインクリニック治療においておさえておくべき薬物相互作用】 オピオイド鎮痛薬の薬物相互作用 トラマドールの薬物相互作用
    住谷 昌彦, 山内 照夫, 松平 浩
    ペインクリニック 35(別冊秋) S398-S406 Oct. 2014
  • がん疼痛マネジメントに対する患者の心理的バリア評価指標の開発―日本語版The Barriers Questionnaire IIの検証―
    榊原直喜, 榊原直喜, 小松浩子, 高橋美賀子, 山内英子, 山内照夫
    日本がん看護学会誌 28(Suppl.) 129-129 Jan. 2014
  • 外来化学療法におけるチーム医療の整備と検証に関する研究 民間総合病院における外来化学療法チーム医療の整備と検証に関する研究
    外来化学療法におけるチーム医療の整備と検証に関する研究 平成25年度 総括・分担研究報告書 19-21 2014
  • 【Up to Date分子標的治療薬】 分子標的治療薬の基礎と今後の展望
    名取 亜希奈, 山内 照夫
    がん看護 19(1) 5-8 Jan. 2014
  • 【薬が分かる!ケアにいかせる!これだけは押さえておきたいがん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬 はや調べノート】 葉酸拮抗薬 メトトレキサート
    山内 照夫
    プロフェッショナルがんナーシング(2013別冊) 80-81 Apr. 2013
  • 【薬が分かる!ケアにいかせる!これだけは押さえておきたいがん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬 はや調べノート】 葉酸拮抗薬 ペメトレキセド
    山内 照夫
    プロフェッショナルがんナーシング(2013別冊) 82-83 Apr. 2013
  • Investigator-initiated trial for PMDA approval in collaboration with the US NCI/CTEP
    Imamura CK, Yamauchi T, Yamauchi H, Jinno H, Kitagawa Y, Nakamura S, Saya H, Ueno NT
    Ann Oncol 24(Supplement 9) ix24 2013 [Refereed]
    Mini symposium 1:"Improvement of the foundations for cancer control"(Msy1-1)in 11th Annual Meeting of the Japanese Society of Medical Oncology, 29–31 August 2013, Sendai, Japan
  • 外来化学療法におけるチーム医療の整備と検証に関する研究 民間総合病院における外来化学療法チーム医療の整備と検証に関する研究
    外来化学療法におけるチーム医療の整備と検証に関する研究 平成24年度 総括・分担研究報告書 16-20 2013
  • 米国NCIとのコラボレーションによる医師主導治験
    山内照夫, 今村知世, 甲斐千晴, 神野浩光, 山内英子, 北川雄光, 佐谷秀行, 中村清吾, 上野直人
    日本乳癌学会学術総会プログラム・抄録集 20th 318-318 May 2012
  • 米国NCIとのコラボレーションによる医師主導治験
    今村知世, 山内照夫, 山内英子, 中村清吾, 神野浩光, 北川雄光, 佐谷秀行, 上野直人
    臨床薬理 42(Supplement) S197 Oct. 2011
  • 【ステロイドの使い方 こんなときどうする?日常診療で上手く使う処方・減量・中止のコツ】 血液/腫瘍内科でのステロイド、こんなときどうする?
    山口 典宏, 山内 照夫
    レジデントノート 13(9) 1543-1550 Oct. 2011
    (1)oncologic emergency時のステロイドは、高カルシウム血症、脊髄圧迫、転移性脳腫瘍による脳圧亢進に対して使用する(2)化学療法による嘔気・嘔吐を和らげるためのステロイドは、嘔気・嘔吐を適切に鑑別して用いる(3)化学療法薬としてのステロイドは、リンパ球系悪性腫瘍に対して用いられる(著者抄録)
  • 【治療に伴う看護特集 ケアに即効!化学療法の薬 抗がん剤・ホルモン剤・分子標的薬 速習覚え書き】 葉酸拮抗薬 メトトレキサート
    山内 照夫
    プロフェッショナルがんナーシング 1(1) 28-29 Feb. 2011
  • 【治療に伴う看護特集 ケアに即効!化学療法の薬 抗がん剤・ホルモン剤・分子標的薬 速習覚え書き】 葉酸拮抗薬 ペメトレキセド
    山内 照夫
    プロフェッショナルがんナーシング 1(1) 30-31 Feb. 2011
  • 【入院患者に臓器不全も併存するときどうする? 腎・心・肝・呼吸器・糖尿病・癌・高齢者など、併存症の注意点】 がんの患者さんが入院してきたら がん治療のゴールはどこなのかを意識しよう!
    山内 照夫
    レジデントノート 12(12) 2103-2108 Dec. 2010
    (1)迅速な診療録レビューと病歴聴取でがん診断名と現在の治療を把握する(2)がん診断の2つのポイント:組織診断(癌種)とステージ(進展度)を押さえる(3)がん治療の2つの目的:治癒と延命・緩和を区別する(4)Oncologic Emergencyを見逃さず、迅速に対応する(5)終末期医療が必要か判断し、緩和ケア科と併診するか、転科するか判断する(著者抄録)
  • 【理解して実践するがん化学療法】 がん細胞の特性
    山内 照夫
    看護技術 56(6) 556-558 May 2010
  • 【理解して実践するがん化学療法】 がん化学療法とは
    山内 照夫
    看護技術 56(6) 559-562 May 2010
  • 腫瘍内科の緩和ケアにおける役割
    日本緩和医療薬学会年会プログラム・要旨集 4th 89 2010
  • 悪性腫瘍と水・電解質異常 悪性腫瘍例における低Na血症の発生頻度とその考察
    芳賀 章子, 山内 照夫, 吉岡 成人
    臨床体液 18(1) 33-35 Oct. 1991

Copyright (c) MEDIA FUSION Co.,Ltd. All rights reserved.